These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 18977777)
21. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. Nelson PA; Powers JN; Estridge TD; Elder EA; Alea AD; Sidhu PK; Sehl LC; DeLustro FA J Biomed Mater Res; 2001; 58(6):710-9. PubMed ID: 11745525 [TBL] [Abstract][Full Text] [Related]
22. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. Chapman WC; Singla N; Genyk Y; McNeil JW; Renkens KL; Reynolds TC; Murphy A; Weaver FA J Am Coll Surg; 2007 Aug; 205(2):256-65. PubMed ID: 17660072 [TBL] [Abstract][Full Text] [Related]
23. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Dorion RP; Hamati HF; Landis B; Frey C; Heydt D; Carey D Arch Pathol Lab Med; 1998 Oct; 122(10):887-94. PubMed ID: 9786349 [TBL] [Abstract][Full Text] [Related]
24. A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. Ofosu FA; Crean S; Reynolds MW Clin Ther; 2009 Apr; 31(4):679-91. PubMed ID: 19446142 [TBL] [Abstract][Full Text] [Related]
31. Preclinical safety of recombinant human thrombin. Heffernan JK; Ponce RA; Zuckerman LA; Volpone JP; Visich J; Giste EE; Jenkins N; Boster D; Pederson S; Knitter G; Palmer T; Wills M; Early RJ; Rogge MC Regul Toxicol Pharmacol; 2007 Feb; 47(1):48-58. PubMed ID: 16971028 [TBL] [Abstract][Full Text] [Related]
32. Achieving hemostasis in the surgical field. Boucher BA; Traub O Pharmacotherapy; 2009 Jul; 29(7 Pt 2):2S-7S. PubMed ID: 19558278 [TBL] [Abstract][Full Text] [Related]
33. Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy. Pavlovich CP; Battiwalla M; Rick ME; Walther MM J Urol; 2001 May; 165(5):1617. PubMed ID: 11342931 [No Abstract] [Full Text] [Related]
34. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application. Kirkeby KM; Aronowitz P Am J Med; 2005 Jul; 118(7):805. PubMed ID: 15989925 [No Abstract] [Full Text] [Related]
36. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Flaherty MJ; Henderson R; Wener MH Ann Intern Med; 1989 Oct; 111(8):631-4. PubMed ID: 2802417 [TBL] [Abstract][Full Text] [Related]
37. Immune responses associated with perioperative exposure and reexposure to topical bovine thrombin do not impair hemostasis. Paterson CA; Pixton GC; Proskin HM; Massaro JM; Morasch M; Cronstein B; Fareed J; Ofosu FA Clin Appl Thromb Hemost; 2011; 17(6):620-32. PubMed ID: 21596694 [TBL] [Abstract][Full Text] [Related]
38. A gelatin-thrombin matrix for hemostasis after endoscopic sinus surgery. Woodworth BA; Chandra RK; LeBenger JD; Ilie B; Schlosser RJ Am J Otolaryngol; 2009; 30(1):49-53. PubMed ID: 19027513 [TBL] [Abstract][Full Text] [Related]
39. Thrombin products: economic impact of immune-mediated coagulopathies and practical formulary considerations. Voils SA Pharmacotherapy; 2009 Jul; 29(7 Pt 2):18S-22S. PubMed ID: 19558281 [TBL] [Abstract][Full Text] [Related]
40. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Zehnder JL; Leung LL Blood; 1990 Nov; 76(10):2011-6. PubMed ID: 2242423 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]